← Back to patent-cliff list
XH-5102
Tier C — Watch / tradeXH-5102
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：JAK2
Indications (approved)：Myeloproliferative neoplasm, Myelofibrosis, Chronic myeloid leukaemia, Essential thrombocythaemia, Polycythaemia vera
Regional status
US
-
EU
-
China
Phase II
2023-04-07
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of XH-5102?
Approved indications include: Myeloproliferative neoplasm, Myelofibrosis, Chronic myeloid leukaemia, Essential thrombocythaemia, Polycythaemia vera.
When does the XH-5102 patent expire?
No public expiry year is available for XH-5102 yet; this page updates once verified.
How do I get a quote for XH-5102 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03